secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0000950170-24-110066
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences enters $50M ATM equity offering with Jefferies for cytisinicline
--------------------------------------------------------------------------------

- Entered Open Market Sale Agreement with Jefferies for at-the-market offering of up to $50M of common stock.
- Jefferies receives up to 3% commission; company has no obligation to sell and may suspend at any time.
- Proceeds to fund clinical development of cytisinicline for smoking cessation and general corporate purposes.
- Offering made under existing S-3 registration statement filed June 28, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000095017024110066/0000950170-24-110066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000095017024110066/achv-20240927.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-110066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer